Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Agios Pharmaceuticals Inc shares valued at $56,000 were sold by Scadden David on Jul 10 ’25. At $40.00 per share, Scadden David sold 1,400 shares. The insider’s holdings dropped to 17,603 shares worth approximately $0.71 million following the completion of this transaction.
Also, Gheuens Sarah sold 11,914 shares, netting a total of over 452,601 in proceeds. Following the sale of shares at $37.99 each, the insider now holds 61,271 shares.
Before that, DAVID SCADDEN had added 1,400 shares to its account. In a trade valued at $56,000, the Director bought Agios Pharmaceuticals Inc shares for $40.00 each.
As published in their initiating research note from H.C. Wainwright on February 24, 2025, Agios Pharmaceuticals Inc [AGIO] has been a Buy and the price target has been revised to $58. Analysts at Scotiabank started covering the stock with ‘”a Sector outperform”‘ outlook in a report released in mid October. Earlier on September 27, 2024, Leerink Partners downgraded its rating. Their new recommendation was “a Market perform” for AGIO stock which previously was a “an Outperform”.
Analyzing AGIO Stock Performance
On last trading session,, Agios Pharmaceuticals Inc [NASDAQ: AGIO] rose 0.90% to $40.35. The stock’s lowest price that day was $40.06, but it reached a high of $40.9499 in the same session. During the last five days, there has been a surge of approximately 2.07%. Over the course of the year, Agios Pharmaceuticals Inc shares have dropped approximately -14.08%.
Support And Resistance Levels for Agios Pharmaceuticals Inc (AGIO)
RSI (Relative Strength Index) is 73.61 on the 14-day chart, showing overbought technical sentiment.
Is Agios Pharmaceuticals Inc subject to short interest?
Stocks of Agios Pharmaceuticals Inc saw a sharp rise in short interest on 2025-06-13 jumping by 0.17 million shares to 4.32 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 4.16 million shares. A jump of 3.83% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 7.43 of the overall float, the days-to-cover ratio (short ratio) jumped to 7.43.
Which companies own the most shares of Agios Pharmaceuticals Inc (AGIO)?
In terms of Agios Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 71 in the next 12 months, up nearly 77.54% from the previous closing price of $39.99. Analysts anticipate Agios Pharmaceuticals Inc stock to reach 71 by 2025, with the lowest price target being 71. In spite of this, 5 analysts ranked Agios Pharmaceuticals Inc stock as Buy at the end of 2025.
